Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

The molecular basis of breast cancer pathological phenotypes.

Heng YJ, Lester SC, Tse GM, Factor RE, Allison KH, Collins LC, Chen YY, Jensen KC, Johnson NB, Jeong JC, Punjabi R, Shin SJ, Singh K, Krings G, Eberhard DA, Tan PH, Korski K, Waldman FM, Gutman DA, Sanders M, Reis-Filho JS, Flanagan SR, Gendoo DM, Chen GM, Haibe-Kains B, Ciriello G, Hoadley KA, Perou CM, Beck AH.

J Pathol. 2017 Feb;241(3):375-391. doi: 10.1002/path.4847. Epub 2016 Dec 29.

2.

Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation.

Nikita ME, Jiang W, Cheng SM, Hantash FM, McPhaul MJ, Newbury RO, Phillips SA, Reitz RE, Waldman FM, Newfield RS.

Thyroid. 2016 Feb;26(2):227-34. doi: 10.1089/thy.2015.0401. Epub 2016 Jan 7.

3.

Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.

Li Y, Bare LA, Bender RA, Sninsky JJ, Wilson LS, Devlin JJ, Waldman FM.

Mol Diagn Ther. 2015 Jun;19(3):169-77. doi: 10.1007/s40291-015-0140-9.

4.

Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ.

Shin SJ, Lal A, De Vries S, Suzuki J, Roy R, Hwang ES, Schnitt SJ, Waldman FM, Chen YY.

Hum Pathol. 2013 Oct;44(10):1998-2009. doi: 10.1016/j.humpath.2013.04.004. Epub 2013 Jun 25.

PMID:
23809857
5.

FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.

Lal A, Chan L, Devries S, Chin K, Scott GK, Benz CC, Chen YY, Waldman FM, Hwang ES.

Breast Cancer Res Treat. 2013 Jun;139(2):381-90. doi: 10.1007/s10549-013-2556-4. Epub 2013 May 28.

PMID:
23712790
6.

Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation.

Moore LE, Jaeger E, Nickerson ML, Brennan P, De Vries S, Roy R, Toro J, Li H, Karami S, Lenz P, Zaridze D, Janout V, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Linehan WM, Merino M, Simko J, Pfeiffer R, Boffetta P, Hewitt S, Rothman N, Chow WH, Waldman FM.

Oncogenesis. 2012 Jun 25;1:e14. doi: 10.1038/oncsis.2012.14.

7.

Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.

Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, Lenz P, Karami S, Linehan WM, Merino M, Chanock S, Boffetta P, Chow WH, Waldman FM, Rothman N.

PLoS Genet. 2011 Oct;7(10):e1002312. doi: 10.1371/journal.pgen.1002312. Epub 2011 Oct 13.

8.

Genomic alterations and phenotype of large compared to small high-grade ductal carcinoma in situ.

Hwang ES, Lal A, Chen YY, DeVries S, Swain R, Anderson J, Roy R, Waldman FM.

Hum Pathol. 2011 Oct;42(10):1467-75. doi: 10.1016/j.humpath.2011.01.002. Epub 2011 Apr 14.

PMID:
21496874
9.

Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast.

Chen YY, Hwang ES, Roy R, DeVries S, Anderson J, Wa C, Fitzgibbons PL, Jacobs TW, MacGrogan G, Peterse H, Vincent-Salomon A, Tokuyasu T, Schnitt SJ, Waldman FM.

Am J Surg Pathol. 2009 Nov;33(11):1683-94. doi: 10.1097/PAS.0b013e3181b18a89.

10.

Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.

Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Chin K, Shim V, Esserman LJ, Waldman FM, Hwang ES.

BMC Cancer. 2009 Aug 18;9:285. doi: 10.1186/1471-2407-9-285.

11.

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

Mitra AP, Pagliarulo V, Yang D, Waldman FM, Datar RH, Skinner DG, Groshen S, Cote RJ.

J Clin Oncol. 2009 Aug 20;27(24):3929-37. doi: 10.1200/JCO.2008.18.5744. Epub 2009 Jul 20.

12.

Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.

Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, Waldman FM, Hwang ES.

Clin Cancer Res. 2009 May 1;15(9):3163-71. doi: 10.1158/1078-0432.CCR-08-2319. Epub 2009 Apr 21.

13.

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer.

Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, Simko JP, Waldman FM, Pieper RO, Parsa AT.

Oncogene. 2009 Jan 15;28(2):306-12. doi: 10.1038/onc.2008.384. Epub 2008 Oct 13.

14.

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.

Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Mukeria A, Holcatova I, Schmidt LS, Toro JR, Karami S, Hung R, Gerard GF, Linehan WM, Merino M, Zbar B, Boffetta P, Brennan P, Rothman N, Chow WH, Waldman FM, Moore LE.

Clin Cancer Res. 2008 Aug 1;14(15):4726-34. doi: 10.1158/1078-0432.CCR-07-4921.

15.

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R.

J Urol. 2008 Sep;180(3):860-5; discussion 865-6. doi: 10.1016/j.juro.2008.05.015. Epub 2008 Jul 17.

PMID:
18635227
16.

Tissue-based research in kidney cancer: current challenges and future directions.

Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, Merino M, Thomas GV, Pins MR, Libermann T, Gillespie J, Tomaszewski JE, Compton CC, Hruszkewycz A, Linehan WM, Atkins MB.

Clin Cancer Res. 2008 Jun 15;14(12):3699-705. doi: 10.1158/1078-0432.CCR-07-4733. Review.

17.

Comparative genomic hybridization.

DeVries S, Gray JW, Pinkel D, Waldman FM, Sudar D.

Curr Protoc Hum Genet. 2001 May;Chapter 4:Unit4.6. doi: 10.1002/0471142905.hg0406s06.

PMID:
18428281
18.

Fluorescence in situ hybridization of ductal lavage samples identifies malignant phenotypes from cytologically normal cells in women with breast cancer.

Adduci KM, Annis CE, DeVries S, Chew KL, Boutin J, Magrane G, Ljung BM, Waldman FM, Esserman LJ.

Cancer. 2007 Jun 25;111(3):185-91.

19.

Identification of a robust gene signature that predicts breast cancer outcome in independent data sets.

Korkola JE, Blaveri E, DeVries S, Moore DH 2nd, Hwang ES, Chen YY, Estep AL, Chew KL, Jensen RH, Waldman FM.

BMC Cancer. 2007 Apr 11;7:61.

20.

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW.

Cancer Cell. 2006 Dec;10(6):529-41.

21.

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW.

Cancer Cell. 2006 Dec;10(6):515-27.

22.

Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression.

Sternlicht MD, Dunning AM, Moore DH, Pharoah PD, Ginzinger DG, Chin K, Gray JW, Waldman FM, Ponder BA, Werb Z.

Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2107-14.

23.

Chromosomal instability in microsatellite-unstable and stable colon cancer.

Trautmann K, Terdiman JP, French AJ, Roydasgupta R, Sein N, Kakar S, Fridlyand J, Snijders AM, Albertson DG, Thibodeau SN, Waldman FM.

Clin Cancer Res. 2006 Nov 1;12(21):6379-85.

24.

Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study.

Grossman HB, Tangen CM, Cordon-Cardo C, Cote R, Waldman FM, De Vere White RW, Karnad AB, Glode M, Crawford ED.

Oncol Rep. 2006 Oct;16(4):807-10.

PMID:
16969498
25.

Ki-67 correlates with in vivo bromodeoxyuridine labeling index in operable breast cancer.

Goodson WH, Moore DH, Waldman FM.

J Clin Oncol. 2006 Aug 10;24(23):3809; author reply 3809. No abstract available.

PMID:
16896010
26.

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM.

BJU Int. 2006 Oct;98(4):756-62. Epub 2006 Jul 7.

27.

Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer.

Deng G, Nguyen A, Tanaka H, Matsuzaki K, Bell I, Mehta KR, Terdiman JP, Waldman FM, Kakar S, Gum J, Crawley S, Sleisenger MH, Kim YS.

Int J Cancer. 2006 Jun 15;118(12):2999-3005.

28.

Bladder cancer stage and outcome by array-based comparative genomic hybridization.

Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P, Simko JP, Waldman FM.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7012-22.

29.

Bladder cancer outcome and subtype classification by gene expression.

Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P, Waldman FM.

Clin Cancer Res. 2005 Jun 1;11(11):4044-55.

30.

Securin is overexpressed in breast cancer.

Ogbagabriel S, Fernando M, Waldman FM, Bose S, Heaney AP.

Mod Pathol. 2005 Jul;18(7):985-90.

31.

Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.

Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland EK, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM.

Clin Cancer Res. 2005 Mar 1;11(5):1791-7.

32.
33.

CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells.

Retz MM, Sidhu SS, Blaveri E, Kerr SC, Dolganov GM, Lehmann J, Carroll P, Simko J, Waldman FM, Basbaum C.

Int J Cancer. 2005 Mar 20;114(2):182-9.

34.

Prognostic relevance of 20q13 gains in sporadic colorectal cancers: a FISH analysis.

Aust DE, Muders M, Köhler A, Schmidt M, Diebold J, Müller C, Löhrs U, Waldman FM, Baretton GB.

Scand J Gastroenterol. 2004 Aug;39(8):766-72.

PMID:
15513363
35.

Patterns of chromosomal alterations in breast ductal carcinoma in situ.

Hwang ES, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Thor A, Ljung BM, Waldman FM.

Clin Cancer Res. 2004 Aug 1;10(15):5160-7.

36.

Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma.

Hwang ES, Nyante SJ, Yi Chen Y, Moore D, DeVries S, Korkola JE, Esserman LJ, Waldman FM.

Cancer. 2004 Jun 15;100(12):2562-72.

37.

High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization.

Nakao K, Mehta KR, Fridlyand J, Moore DH, Jain AN, Lafuente A, Wiencke JW, Terdiman JP, Waldman FM.

Carcinogenesis. 2004 Aug;25(8):1345-57. Epub 2004 Mar 4.

PMID:
15001537
38.

Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis.

Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY, Chew KL, Dairkee SH, Jensen RM, Waldman FM.

Cancer Res. 2003 Nov 1;63(21):7167-75.

39.

Optimizing stringency for expression microarrays.

Korkola JE, Estep AL, Pejavar S, DeVries S, Jensen R, Waldman FM.

Biotechniques. 2003 Oct;35(4):828-35.

40.

P53 alterations in bladder tumors from arsenic and tobacco exposed patients.

Moore LE, Smith AH, Eng C, DeVries S, Kalman D, Bhargava V, Chew K, Ferreccio C, Rey OA, Hopenhayn C, Biggs ML, Bates MN, Waldman FM.

Carcinogenesis. 2003 Nov;24(11):1785-91. Epub 2003 Aug 14.

PMID:
12919957
41.

Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors.

Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S, Carroll P, Kuo WL, Pinkel D, Albertson D, Cordon-Cardo C, Jain AN, Waldman FM.

Cancer Res. 2003 Jun 1;63(11):2872-80.

42.

Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder.

Cheng J, Huang H, Pak J, Shapiro E, Sun TT, Cordon-Cardo C, Waldman FM, Wu XR.

Cancer Res. 2003 Jan 1;63(1):179-85.

43.

Arsenic-related chromosomal alterations in bladder cancer.

Moore LE, Smith AH, Eng C, Kalman D, DeVries S, Bhargava V, Chew K, Moore D 2nd, Ferreccio C, Rey OA, Waldman FM.

J Natl Cancer Inst. 2002 Nov 20;94(22):1688-96.

PMID:
12441324
44.

High resolution analysis of chromosome 18 alterations in ulcerative colitis-related colorectal cancer.

Terdiman JP, Aust DE, Chang CG, Willenbucher RF, Baretton GB, Waldman FM.

Cancer Genet Cytogenet. 2002 Jul 15;136(2):129-37.

PMID:
12237237
45.

Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization.

Thor AD, Eng C, Devries S, Paterakos M, Watkin WG, Edgerton S, Moore DH 2nd, Etzell J, Waldman FM.

Hum Pathol. 2002 Jun;33(6):628-31.

PMID:
12152162
46.
47.

The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis.

Aust DE, Terdiman JP, Willenbucher RF, Chang CG, Molinaro-Clark A, Baretton GB, Loehrs U, Waldman FM.

Cancer. 2002 Mar 1;94(5):1421-7.

48.

Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer.

Wilhelm M, Veltman JA, Olshen AB, Jain AN, Moore DH, Presti JC Jr, Kovacs G, Waldman FM.

Cancer Res. 2002 Feb 15;62(4):957-60.

49.

Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization.

Gong G, DeVries S, Chew KL, Cha I, Ljung BM, Waldman FM.

Clin Cancer Res. 2001 Aug;7(8):2410-4.

50.

HER2 protein expression and gene amplification in androgen-independent prostate cancer.

Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D.

Am J Clin Pathol. 2001 Aug;116(2):234-9.

PMID:
11488070

Supplemental Content

Loading ...
Support Center